Cytogenetic alterations in meningioma tumors and their impact on disease outcome;Alteraciones citogenéticas en meningiomas y su impacto en la evolución de la enfermedad

Medicina Clinica

Volumn 128, Issue 6, 2007, Pages 226-232

  Sayagués, José María ^a,c   Tabernero, María Dolores ^b   Maíllo, Ángel ^b  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c Centro de Investigacion del Cancer   (Spain)

Author keywords

Cariotype; FISH; Genetics abnormalities; Meningioma; Recurrence

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2B; DNA BINDING PROTEIN; MERLIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAM22; PROTEIN CLH22; PROTEIN GAR22; PROTEIN MN1; PROTEIN P14ARF; PROTEIN P16INK4A; PROTEIN RRP22; PROTEIN SMARCB1; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CHROMOSOME 22; CHROMOSOME ABERRATION; CYTOGENETICS; DISEASE COURSE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE LOCATION; GENE MUTATION; HUMAN; KARYOTYPE; MENINGIOMA; MONOSOMY; ONTOGENY; OUTCOME ASSESSMENT; PROGNOSIS; REVIEW;

EID: 33847754288     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(07)72543-5     Document Type: Review

References (110)

1. Gottfried ON, Gluf W, Quinones-Hinojosa A, Kan P, Schmidt MH. Spinal meningiomas: surgical management and outcome. Neurosurg Focus. 2003;14:e2.
2. King AT, Sharr MM, Gullan RW, Bartlett JR. Spinal meningiomas: a 20-year review. Br J Neurosurg. 1998;12:521-6.
3. Longstreth WT Jr, Dennis LK, McGuire VM, Drangsholt MT, Koepsell TD. Epidemiology of intracranial meningioma. Cancer. 1993;72:639-48.
4. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61:215-25.
5. Bondy M, Ligon BL. Epidemiology and etiology of intracranial meningiomas: a review. J Neurooncol. 1996;29:197-205.
6. Black PM. Meningiomas. Neurosurgery. 1993;32:643-57.
7. Rohringer M, Sutherland GR, Louw DF, Sima AA. Incidence and clinicopathological features of meningioma. J Neurosurg. 1989;71:665-72.
8. Gursan N, Gundogdu C, Albayrak A, Kabalar ME. Immunohistochemical detection of progesterone receptors and the correlation with Ki-67 labeling indices in paraffin-embedded sections of meningiomas. Int J Neurosci. 2002;112:463-70.
9. Wolfsberger S, Doostkam S, Boecher-Schwarz HG, Roessler K, Van Trotsenburg M, Hainfellner JA, et al. Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature. Neurosurg Rev. 2004;274:238-45.
10. Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL. Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg. 1985;62:18-24.
11. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194:23-8.
12. Nowell PC. Mechanisms of tumor progression. Cancer Res, 1986;46:2203-7.
13. Collins VP, Nordenskjold M, Dumanski JP. The molecular genetics of meningiomas. Brain Pathol. 1990;1:19-24.
14. Dumanski JP, Rouleau GA, Nordenskjold M, Collins VP. Molecular genetic analysis of chromosome 22 in 81 cases of meningioma. Cancer Res. 1990;50:5863-7.
15. López-Ginés C, Piquer J, Cerda-Nicolás M, Barcia-Salorio J, Barcia-Marino C. Meningiomas: karyotypes and histological patterns. Clin Neuropathol. 1989;8:130-3.
16. Zang KD. Cytological and cytogenetical studies on human meningioma. Cancer Genet Cytogenet. 1982;6:249-74.
17. Arnoldus EP, Wolters LB, Voormolen JH, Van Duinen SG, Raap AK, Van der PM, et al. Interphase cytogenetics: a new tool for the study of genetic changes in brain tumors. J Neurosurg. 1992;76:997-1003.
18. Poulsgard L, Ronne M, Schroder HD. Cytogenetic studies of 19 meningiomas and their clinical significance. I. Anticancer Res. 1989;9:109-12.
19. Vagner-Capodano AM, Grisoli F, Gambarelli D, Sedan R, Pellet W, De Victor B. Correlation between cytogenetic and histopathological findings in 75 human meningiomas. Neurosurgery. 1993;32:892-900.
20. Katsuyama J, Papenhausen PR, Herz F, Gazivoda P, Hirano A, Koss LG. Chromosome abnormalities in meningiomas. Cancer Genet Cytogenet. 1986;22:63-8.
21. Leon SP, Zhu J, Black PM. Genetic aberrations in human brain tumors. Neurosurgery. 1994;34:708-22.
22. Zankl H, Huwer H, Zang KD. Cytogenetic studies on the nucleolar organizer region [NOR] activity in meningioma cells with normal and hypodiploid karyotypes. Cancer Genet Cytogenet. 1982;6:47-53.
23. Scholz M, Gottschalk J, Striepecke E, Firsching R, Harders A, Fuzesi L. Intratumorous heterogeneity of chromosome 10 and 17 in meningiomas using non-radioactive in situ hybridization. J Neurosurg Sci. 1996;40:17-23.
24. Muller P, Henn W, Niedermayer I, Ketter R, Feiden W, Steudel WI, et al. Deletion of chromosome 1p and loss of expression of alkaline phosphatase indicate progression of meningiomas. Clin Cancer Res. 1999;5:3569-77.
25. Zattara-Cannoni H, Gambarelli D, Dufour H, Figarella D, Vollot F, Grisoli F, et al. Contribution of cytogenetics and FISH in the diagnosis of meningiomas. A study of 189 tumors. Ann Genet. 1998;41:164-75.
26. Cai DX, Banerjee R, Scheithauer BW, Lohse CM, Kleinschmidt-Demasters BK, Perry A. Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: diagnostic and prognostic implications. J Neuropathol Exp Neurol. 2001;60:628-36.
27. López-Gines C, Cerda-Nicolás M, Gil-Benso R, Barcia-Salorio JL, Llombart-Bosch A. Loss of 1p in recurrent meningiomas. A comparative study in successive recurrences by cytogenetics and fluorescence in situ hybridization. Cancer Genet Cytogenet. 2001;125:119-24.
28. Zang KD, Singer H. Chromosomal consitution of meningiomas. Nature. 1967;216:84-5.
29. Benedict WF, Porter IH, Brown CD, Florentin RA. Cytogenetic diagnosis of malignancy in recurrent meningioma. Lancet. 1970;1:971-3.
30. Portero JA, García QL, Rey JA, Ayuso C. Meningiomas y su implicación citogenética. Rev Clin Esp. 1980;157:305-8.
31. Blin N, Mullenbach R, Suijkerbuijk R, Herzog R, Meese E. Cosmid mapping and locus linkage within the human chromosomal region 22q13.1. Cancer Genet Cytogenet. 1993;70:108-11.
32. Lekanne Deprez RH, Groen NA, Van Biezen NA, Hagemeijer A, Van Drunen E, Koper JW, et al. A t(4;22) in a meningioma points to the localization of a putative tumor-suppressor gene. Am J Hum Genet. 1991;48:783-90.
33. Seizinger BR, Martuza RL, Gusella JF. Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma. Nature. 1986;322:644-7.
34. Carlson KM, Bruder C, Nordenskjold M, Dumanski JP. 1p and 3p deletions in meningiomas without detectable aberrations of chromosome 22 identified by comparative genomic hybridization. Genes Chromosomes Cancer. 1997;20:419-24.
35. Cerda-Nicolás M, López-Gines C, Pérez-Bacete M, Talamantes F, Roldán P. Monosomía 1p y fosfatasa alcalina en meningiomas. Estudio clinicopatológico, histoquímico y genético en 10 tumores. Med Clin (Barc). 2002;118:655-8.
36. Bello MJ, De Campos JM, Kusak ME, Vaquero J, Sarasa JL, Pestana A, et al. Allelic loss at 1p is associated with tumor progression of meningiomas. Genes Chromosomes Cancer. 1994;9:296-8.
37. Lamszus K, Kluwe L, Matschke J, Meissner H, Laas R, Westphal M. Allelic losses at 1p, 9q, 10q, 14q, and 22q in the progression of aggressive meningiomas and undifferentiated meningeal sarcomas. Cancer Genet Cytogenet. 1999;110:103-10.
38. Lomas J, Bello MJ, Arjona D, González-Gómez P, Alonso ME, De Campos JM, et al. Analysis of p73 gene in meningiomas with deletion at 1p. Cancer Genet Cytogenet. 2001;129:88-91.
39. Sayagués JM, Tabernero MD, Maillo A, Espinosa A, Rasillo A, Díaz P, et al. Intratumoral patterns of clonal evolution in meningiomas as defined by multicolor interphase fluorescence in situ hybridization (FISH): is there a relationship between histopathologically benign and atypical/anaplastic lesions? J Mol Diag. 2004;6:316-25.
40. Griffin CA, Hruban RH, Long PP, Miller N, Volz P, Carson B, et al. Chromosome abnormalities in meningeal neoplasms: do they correlate with histology? Cancer Genet Cytogenet. 1994;78:46-52.
41. Lindblom A, Ruttledge M, Collins VP, Nordenskjold M, Dumanski JP. Chromosomal deletions in anaplastic meningiomas suggest multiple regions outside chromosome 22 as important in tumor progression. Int J Cancer. 1994;56:354-7.
42. Rempel SA, Schwechheimer K, Davis RL, Cavenee WK, Rosenblum ML. Loss of heterozygosity for loci on chromosome 10 is associated with morphologically malignant meningioma progression. Cancer Res. 1993;53:2386-92.
43. Leone PE, Bello MJ, Mendiola M, Kusak ME, De Campos JM, Vaquero J, et al. Allelic status of 1p, 14q, and 22q and NF2 gene mutations in sporadic schwannomas. Int J Mol Med. 1998;1:889-92.
44. Tse JY, Ng HK, Lau KM, Lo KW, Poon WS, Huang DP. Loss of heterozygosity of chromosome 14q in low- and high-grade meningiomas. Hum Pathol. 1997;28:779-85.
45. Kim JH, Lee SH, Rhee CH, Park SY, Lee JH. Loss of heterozygosity on chromosome 22q and 17p correlates with aggressiveness of meningiomas. J Neurooncol. 1998;40:101-6.
46. Buschges R, Bostrom J, Wolter M, Blaschke B, Weber RG, Lichter P, et al. Analysis of human meningiomas for aberrations of the MADH2, MADH4, APM-1 and DCC tumor suppressor genes on the long arm of chromosome 18. Int J Cancer. 2001;92:551-4.
47. Bostrom J, Meyer-Puttlitz B, Wolter M, Blaschke B, Weber RG, Lichter P, et al. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. Am J Pathol. 2001;159:661-9.
48. Yamada K, Kasama M, Kondo T, Shinoura N, Yoshioka M. Chromosome studies in 70 brain tumors with special attention to sex chromosome loss and single autosomal trisomy. Cancer Genet Cytogenet. 1994;73:46-52.
49. Sayagués JM, Tabernero MD, Maíllo A, Díaz P, Rasillo A, Bortoluci A, et al. Incidence of numerical chromosome aberrations in meningioma tumors as revealed by fluorescence in situ hybridization (FISH) using 10 chromosome-specific probes. Clinical Cytometry. 2002;50:153-9.
50. Maruno M, Yoshimine T, Muhammad AK, Ninomiya H, Hayakawa T. Chromosomal losses and gains in meningiomas: comparative genomic hybridization (CGH) study of the whole genome. Neurol Res. 1998;20:612-6.
51. Kasai H, Kawamoto K. Cytogenical analysis of brain tumors by FISH (fluorescence in situ hybridization) and FCM (flow cytometry). Noshuyo Byori. 1995;12:75-82.
52. Khan J, Parsa NZ, Harada T, Meltzer PS, Carter NP. Detection of gains and losses in 18 meningiomas by comparative genomic hybridization. Cancer Genet Cytogenet. 1998;103:95-100.
53. Dumanski JP, Carlbom E, Collins VP, Nordenskjold M. Deletion mapping of a locus on human chromosome 22 involved in the oncogenesis of meningioma. Proc Natl Acad Sci U S A. 1987;84:9275-9.
54. Sawyer JR, Husain M, Pravdenkova S, Krisht A, Al Mefty O. A role for telomeric and centromeric instability in the progression of chromosome aberrations in meningioma patients. Cancer. 2000;88:440-53.
55. Simon M, Kokkino AJ, Warnick RE, Tew JM Jr, Von Deimling A, Menon AG. Role of genomic instability in meningioma progression. Genes Chromosomes Cancer. 1996;16:265-9.
56. Simon M, Von Deimling A, Larson JJ, Wellenreuther R, Kaskel P, Waha A, et al. Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression. Cancer Res. 1995;55:4696-701.
57. Leone PE, Bello MJ, De Campos JM, Vaquero J, Sarasa JL, Pestana A, et al. NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. Oncogene. 1999;18:2231-9.
58. Ketter R, Henn W, Niedermayer I, Steilen-Gimbel H, Konig J, Zang KD, et al. Predictive value of progression-associated chromosomal aberrations for the prognosis of meningiomas: a retrospective study of 198 cases. J Neurosurg. 2001;95:601-7.
59. Louis DN, Scheithauer BW, Budka H, Von Deimling A, Kepes JJ. Meningeal tumours. En: Kleihues P, Cavenee WK, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of the nervous system. Lyon: 2000; p. 176-84.
60. Weber RG, Bostrom J, Wolter M, Baudis M, Collins VP, Reifenberger G, et al. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci U S A. 1997;94:14719-24.
61. Ruttledge MH, Sarrazin J, Rangaratnam S, Phelan CM, Twist E, Merel P, et al. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet. 1994;6:180-4.
62. Lekanne Deprez RH, Bianchi AB, Groen NA, Seizinger BR, Hagemeijer A, Van Drunen E, et al. Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas. Am J Hum Genet. 1994;54:1022-9.
63. Merel P, Haong-Xuan K, Sanson M, Moreau-Aubry A, Bijlsma EK, Lazaro C, et al. Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas. Genes Chromosomes Cancer. 1995;13:211-6.
64. Rey JA, Bello MJ, De Campos JM, Vaquero J, Kusak ME, Sarasa JL, et al. Abnormalities of chromosome 22 in human brain tumors determined by combined cytogenetic and molecular genetic approaches. Cancer Genet Cytogenet. 1993;66:1-10.
65. Lekanne Deprez RH, Riegman PH, Van Drunen E, Warringa UL, Groen NA, Stefanko SZ, et al. Cytogenetic, molecular genetic and pathological analyses in 126 meningiomas. J Neuropathol Exp Neurol. 1995;54:224-35.
66. Ng HK, Lau KM, Tse JY, Lo KW, Wong JH, Poon WS, et al. Combined molecular genetic studies of chromosome 22q and the neurofibromatosis type 2 gene in central nervous system tumors. Neurosurgery. 1995;37:764-73.
67. Seizinger BR, De la Monte S, Atkins L, Gusella JF, Martuza RL. Molecular genetic approach to human meningioma: loss of genes on chromosome 22. Proc Natl Acad Sci U S A. 1987;84:5419-23.
68. Ueki K, Wen-Bin C, Narita Y, Asai A, Kirino T. Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas. Cancer Res. 1999;59:5995-8.
69. Gusella JF, Ramesh V, MacCollin M, Jacoby LB. Neurofibromatosis 2: loss of merlin's protective spell. Curr Opin Genet Dev. 1996;6:87-92.
70. Ikeda S, Kimura H, Honma E, Shibata T, Yamazaki S, Hashimoto K, et al. A study of reduction of NF 2 protein, mRNA and loss of 22 q in sporadic meningiomas. No To Shinkei. 2000;52:973-7.
71. Wellenreuther R, Kraus JA, Lenartz D, Menon AG, Schramm J, Louis DN, et al. Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol. 1995;146:827-32.
72. Evans JJ, Jeun SS, Lee JH, Harwalkar JA, Shoshan Y, Cowell JK, et al. Molecular alterations in the neurofibromatosis type 2 gene and its protein rarely occurring in meningothelial meningiomas. J Neurosurg. 2001;94:111-7.
73. Hitotsumatsu T, Iwaki T, Kitamoto T, Mizoguchi M, Suzuki SO, Hamada Y, et al. Expression of neurofibromatosis 2 protein in human brain tumors: an immunohistochemical study. Acta Neuropathol (Berl). 1997;93:225-32.
74. Lomas J, Bello MJ, Alonso ME, González-Gómez P, Arjona D, Kusak ME, et al. Loss of chromosome 22 and absence of NF2 gene mutation in a case of multiple meningiomas. Hum Pathol. 2002;33:375-8.
75. Ruttledge MH, Xie YG, Han FY, Peyrard M, Collins VP, Nordenskjold M, et al. Deletions on chromosome 22 in sporadic meningioma. Genes Chromosomes Cancer. 1994;10:122-30.
76. Gutmann DH, Donahoe J, Perry A, Lemke N, Gorse K, Kittiniyom K, et al. Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Hum Mol Genet. 2000;9:1495-500.
77. Perry A, Cai DX, Scheithauer BW, Swanson PE, Lohse CM, Newsham IF, et al. Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. J Neuropathol Exp Neurol. 2000;59:872-9.
78. Prempree T, Amornmarn R, Faillace WJ, Arce CA, Nguyen TQ. 1;19 translocation in human meningioma. Cancer. 1993;71:2306-11.
79. Bello MJ, De Campos JM, Vaquero J, Kusak ME, Sarasa JL, Rey JA. High-resolution analysis of chromosome arm 1p alterations in meningioma. Cancer Genet Cytogenet. 2000;120:30-6.
80. Ishino S, Hashimoto N, Fushiki S, Date K, Mori T, Fujimoto M, et al. Loss of material from chromosome arm 1p during malignant progression of meningioma revealed by fluorescent in situ hybridization. Cancer. 1998;83:360-6.
81. Zang KD. Meningioma: a cytogenetic model of a complex benign human tumor, including data on 394 karyotyped cases. Cytogenet Cell Genet. 2001;93:207-20.
82. Zhu J, Guo SZ, Beggs AH, Maruyama T, Santarius T, Dashner K, et al. Microsatellite instability analysis of primary human brain tumors. Oncogene. 1996;12:1417-23.
83. Leuraud P, Marie Y, Robin E, Huguet S, He J, Mokhtari K, et al. Frequent loss of 1p32 region but no mutation of the p18 tumor suppressor gene in meningiomas. J Neurooncol. 2000;50:207-13.
84. Piaskowski S, Rieske P, Szybka M, Wozniak K, Bednarek A, Pluciennik E, et al. GADD45A and EPB41 as tumor suppressor genes in meningioma pathogenesis. Cancer Genet Cytogenet. 2005;162:63-7.
85. Niedermayer I, Feiden W, Henn W, Steilen-Gimpel H, Steudel WI, Zang KD. Loss of alkaline phosphatase activity in meningiomas: a rapid histochemical technique indicating progression-associated deletion of a putative tumor suppressor gene on the distal part of the short arm of chromosome 1. J Neuropathol Exp Neurol. 1997;56:879-86.
86. Menon AG, Rutter JL, Von Sattel JP, Synder H, Murdoch C, Blumenfeld A, et al. Frequent loss of chromosome 14 in atypical and malignant meningioma: identification of a putative «tumor progression» locus. Oncogene. 1997;14:611-6.
87. Lusis EA, Watson MA, Chicoine MR, Lyman M, Roerig P, Reifenberger G, et al. Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res. 2005;65:7121-6.
88. Peters N, Wellenreuther R, Rollbrocker B, Hayashi Y, Meyer-Puttlitz B, Duerr EM, et al. Analysis of the PTEN gene in human meningiomas. Neuropathol Appl Neurobiol. 1998;24:3-8.
89. Bostrom J, Cobbers JM, Wolter M, Tabatabai G, Weber RG, Lichter P, et al. Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res. 1998;58:29-33.
90. Perry A, Banerjee R, Lohse CM, Kleinschmidt-Demasters BK, Scheithauer BW. A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas. Brain Pathol. 2002;12:183-90.
91. Fulci G, Ishii N, Maurici D, Gernert KM, Hainaut P, Kaur B, et al. Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion. Cancer Res. 2002;62:2897-905.
92. Joachim T, Ram Z, Rappaport ZH, Simon M, Schramm J, Wiestler OD, et al. Comparative analysis of the NF2, TP53, PTEN, KRAS, NRAS and HRAS genes in sporadic and radiation-induced human meningiomas. Int J Cancer. 2001;94:218-21.
93. Verheijen FM, Sprong M, Kloosterman JM, Blaauw G, Thijssen JH, Blankenstein MA. TP53 mutations in human meningiomas. Int J Biol Markers. 2002; 7:42-8.
94. Wang JL, Zhang ZJ, Hartman M, Smits A, Westermark B, Muhr C, et al. Detection of TP53 gene mutation in human meningiomas: a study using immunohistochemistry, polymerase chain reaction/single-strand conformation polymorphism and DNA sequencing techniques on paraffin-embedded samples. Int J Cancer. 1995;64:223-8.
95. Buschges R, Ichimura K, Weber RG, Reifenberger G, Collins VP. Allelic gain and amplification on the long arm of chromosome 17 in anaplastic meningiomas. Brain Pathol. 2002;12:145-53.
96. Cai DX, James CD, Scheithauer BW, Couch FJ, Perry A. PS6K amplification characterizes a small subset of anaplastic meningiomas. Am J Clin Pathol. 2001;115:213-8.
97. Ayerbe J, Lobato RD, De la Cruz J, Alday R, Rivas JJ, Gómez PA, et al. Risk factors predicting recurrence in patients operated on for intracranial meningioma. A multivariate analysis. Acta Neurochir (Wien). 1999;141:921-32.
98. Mathiesen T, Lindquist C, Kihlstrom L, Karlsson B. Recurrence of cranial base meningiomas. Neurosurgery. 1996;39:2-7.
99. Hunt DP. Predicting meningioma recurrence. Royal College of Radiologists Annual Undergraduate Prize in Clinical Oncology, 1999. Clin Oncol (R Coll Radiol). 1999;11:398-404.
100. Stafford SL, Perry A, Suman VJ, Meyer FB, Scheithauer BW, Lohse CM, et al. Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin Proc. 1998;73:936-42.
101. Mahmood A, Caccamo DV, Tomecek FJ, Malik GM. Atypical and malignant meningiomas: a clinicopathological review. Neurosurgery. 1993;33:955-63.
102. George B. Combined modality therapy of central nervous system tumors. En: Petrovich Z, Brady LW, Apuzzo ML, editors. Surgical therapy and problems in the treatmet of meningiomas. Berlin: Springer-Velag; 2001. p. 251-63.
103. Zellner A, Meixensberger J, Roggendorf W, Janka M, Hoehn H, Roosen K. DNA ploidy and cell-cycle analysis in intracranial meningiomas and hemangiopericytomas: a study with high-resolution DNA flow cytometry. Int J Cancer. 1998;79:116-20.
104. Cruz-Sánchez FF, Miquel R, Rossi ML, Figols J, Palacín A, Cardesa A. Clinico-pathological correlations in meningiomas: a DNA and immunohistochemical study. Histol Histopathol. 1993;8:1-8.
105. García R, Bueno A, Castanon S, Ruiz-Barnes P, De Campos MJ, Kusak E, et al. Study of the DNA content by flow cytometry and proliferation in 281 brain tumors. Oncology. 1997;54:112-7.
106. Maíllo A, Díaz P, Sayagués JM, Blanco A, Tabernero MD, Ciudad J, et al. Gains of chromosome 22 by fluorescence in situ hybridization in the context of an hyperdiploid karyotype are associated with aggressive clinical features in meningioma patients. Cancer. 2001;92:377-85.
107. Pfisterer WK, Hank NC, Preul MC, Hendricks WP, Pueschel J, Coons SW, et al. Diagnostic and prognostic significance of genetic regional heterogeneity in meningiomas. Neurooncol. 2004;6:290-9.
108. Prowald A, Wemmert S, Biehl C, Storck S, Martin T, Henn W, et al. Interstitial loss and gain of sequences on chromosome 22 in meningiomas with normal karyotype. Int J Oncol. 2005;26:385-93.
109. Maillo A, Orfao A, Sayagués JM, Díaz P, Gomez-Moreta JA, Caballero M, et al. New classification scheme for the prognostic stratification of meningioma on the basis of chromosome 14 abnormalities, patient age, and tumor histopathology. J Clin Oncol. 2003;21:3285-95.
110. Espinosa AB, Tabernero MD, Maíllo A, Sayagués JM, Ciudad J, Merino M, et al. The cytogenetic relationship between primary and recurrent meningiomas points to the need for new treatment strategies in cases at high risk of relapse. Clin Cancer Res. 2006;12:772-80.